SanegeneBio
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Tradecenter Ste 5500, Woburn, Massac...Website
www.sanegenebio.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for patients worldwide. This vision is being realized by advancing a fast-growing pipeline, which includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for four experimental medicines to-date, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage the company's industry-leading and differentiated LEAD tissue-selective RNAi delivery technology.Explore more
SanegeneBio Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SanegeneBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if SanegeneBio has recently received funding, and reach out quickly before it becomes old news!
SanegeneBio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at SanegeneBio
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if SanegeneBio had a recent Job posting/layoffs
Earning: See what the market has to say on SanegeneBio recently announced quarterly report
Check out if SanegeneBio is spiking on competitors!
Product Launch: Get notified when SanegeneBio launches new products
Funding: Get notified immidiatlly once SanegeneBio has new funding data
Recommended Actions
Find VP level buyers at SanegeneBio
Find 3 more new buyers
Compare Similar Companies to SanegeneBio
Compare insights from companies similar to SanegeneBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SanegeneBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SanegeneBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SanegeneBio.
SanegeneBio financials insights
Gather financial insights about SanegeneBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$110M
SanegeneBio Tech Stack
A closer look at the technologies used by SanegeneBio
Most Recent Scoops
Hiring Plans
SanegeneBio has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Clinical Trials, Clinical Study Reports, Source Document, Biochemistry, Clinical Medicine, Life Sciences, and Clinical Trial Development.
Hiring Plans
Open Position
Open Position
Funding
Funding
Open Position
SanegeneBio News & Media
SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties -...SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties - Genentech will be responsible for the subsequent clinical development and commercialization globally BOSTON, SHANGHAI and SUZHOU, China, Feb. 2, 2026 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology companyInnovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of...SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding SanegeneBio
Sign Up For FreeTo access detailed company insights
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, im... Read More
